Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RET5: Topotecan and Vincristine in Retinoblastoma
NCT00186888Phase 3Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Apr 2005
- Primary completion
- Nov 2013
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 3, open-label trial of topotecan liposome in retinoblastoma (Rb) (3 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Stratum B Response to Window Therapy, Ocular Survival and 1 more. Started Apr 2005; status: completed.
02
Drugs
topotecan liposome
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on NCT00186888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00186888.